Julio Garcia-Aguilar
Surgeon who led OPRA, showing half of rectal cancer patients can keep their rectum with total neoadjuvant therapy and watch-and-wait.
Overview
Julio Garcia-Aguilar led the OPRA trial, which showed total neoadjuvant therapy followed by watch-and-wait for complete responders preserves the rectum in about half of patients with locally advanced rectal cancer without compromising survival, and that consolidation chemotherapy after chemoradiation is the better sequence. He chairs colorectal surgery at MSKCC and leads organ-preservation trials in the Alliance.
Pages like this
not linked directly; found by shared links- PersonAngelita Habr-Gama
Shares Colorectal cancer and the tags colorectal, surgery, organ-preservation.
- PersonCornelis J. H. van de Velde
Shares Colorectal cancer and the tags colorectal, surgery.
- PersonYuman Fong
Shares Robotic & minimally invasive surgery, Colorectal cancer and the tag surgery.
- PersonAndrea Cercek
Shares Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency, Memorial Sloan Kettering Cancer Center, Colorectal cancer.
- PersonPedro T. Ramirez
Shares Robotic & minimally invasive surgery and the tag surgery.
- PersonArnaud Méjean
Shares Robotic & minimally invasive surgery and the tag surgery.
- PersonDeborah Schrag
Shares Memorial Sloan Kettering Cancer Center, Colorectal cancer and the tag colorectal.
- PersonMarc G. Besselink
Shares Robotic & minimally invasive surgery and the tag surgery.